+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bloodstream Infection Testing Market - Global Forecast to 2030- Product Image
Bloodstream Infection Testing Market - Global Forecast to 2030- Product Image
Sale

Bloodstream Infection Testing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977727
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bloodstream Infection Testing Market grew from USD 1.20 billion in 2024 to USD 1.30 billion in 2025. It is expected to continue growing at a CAGR of 7.73%, reaching USD 1.88 billion by 2030.

The battle against bloodstream infections is intensifying as healthcare systems worldwide confront rising morbidity and mortality rates. Rapid, accurate diagnosis of these infections can mean the difference between targeted therapy and broad-spectrum antibiotic overuse, which fuels antimicrobial resistance. As pathogens evolve and new detection technologies emerge, clinical decision-makers face the critical challenge of selecting testing methods that balance speed, sensitivity, and cost-effectiveness. This executive summary presents a comprehensive overview of current testing modalities, market dynamics, and strategic considerations to empower laboratory directors, hospital administrators, and diagnostic innovators in optimizing patient outcomes and operational efficiency.

Transformative Shifts in the Bloodstream Infection Diagnostic Landscape

Over the past decade, bloodstream infection diagnostics have undergone transformative shifts driven by technological breakthroughs and changing clinical priorities. Traditional culture-based techniques, once the gold standard, are being augmented by molecular assays that reduce time to pathogen identification from days to hours. Next-generation sequencing platforms now enable comprehensive pathogen profiling in a single run, while real-time polymerase chain reaction systems deliver rapid, multiplexed detection of bacterial, viral, and fungal targets. Meanwhile, the integration of digital microarrays and immunoassays into automated workflows has streamlined lab operations and improved reproducibility.

These technological advancements coincide with a healthcare emphasis on antimicrobial stewardship, forcing laboratories to adopt tests that guide targeted therapy. In parallel, growing demand for point-of-care diagnostics in emergency departments and intensive care units is catalyzing the development of portable, easy-to-use detection modes. As a result, the diagnostic landscape is evolving toward a hybrid model that leverages both high-throughput central lab systems and decentralized rapid assays, reflecting a fundamental shift in how bloodstream infections are diagnosed and managed.

Cumulative Impact of U.S. Tariffs on Diagnostic Procurement and Supply Chain

In response to recent trade policies, the imposition of tariffs on diagnostic reagents and instrumentation has reshaped procurement strategies across the United States. Equipment manufacturers have adapted by localizing assembly operations and sourcing components domestically to mitigate cost impacts. Reagent suppliers, facing increased import duties, have renegotiated supply contracts and explored alternative raw material providers to maintain competitive pricing. These tariff-driven adjustments have prompted laboratories to reevaluate their testing portfolios, prioritizing assays with lower total cost of ownership and flexible reagent formats.

Diagnostic developers have also accelerated collaborations with contract manufacturing organizations in tariff-exempt zones to ensure continuity of supply. Meanwhile, end users are increasingly seeking reagent rental agreements and reagent-on-demand models that shift capital expenditure toward operational expenditure, thereby reducing vulnerability to tariff fluctuations. Overall, the 2025 tariff environment has fostered greater supply chain resilience, encouraging market participants to adopt innovative procurement and partnership strategies to streamline costs and sustain access to cutting-edge testing technologies.

Key Segmentation Insights Across Testing Modalities and End-User Needs

Deep examination of the market through multiple segmentation lenses reveals nuanced opportunities for stakeholders. Based on testing type, molecular assays have captured a growing share by offering rapid turnaround times compared to chromatography and conventional methods, yet chromatography remains indispensable for confirmatory analyses. Within molecular testing, PCR techniques-encompassing multiplex and real-time formats-dominate acute care settings due to their blend of speed and sensitivity, while de nova and Sanger sequencing remain vital for comprehensive pathogen characterization and surveillance.

Exploring technology type further, immunoassays continue to serve as cost-effective screening tools, microarrays are carving a niche in high-throughput laboratories, and next-generation sequencing platforms are transforming genomic epidemiology. Pathogen type segmentation underscores the continued prevalence of bacterial bloodstream infections, with gram-negative bacteria driving the most severe sepsis cases and gram-positive organisms remaining common in catheter-related infections. Fungal diagnostics are experiencing incremental adoption, especially among immunocompromised patients, while RNA and DNA virus detection has surged amid heightened outbreak vigilance.

Clinical applications are shifting toward in-patient rapid testing to accelerate clinical decisions, supported by laboratory testing workflows optimized for throughput. End-user analysis highlights that hospitals and clinics, particularly emergency departments, demand point-of-care solutions, while diagnostic laboratories invest in both instruments and reagents based on volume and complexity needs. Academic and research institutes leverage advanced software and analytics tools for pathogen genomics studies, and pediatric, geriatric, adult, and neonatal care settings require assays validated across diverse age groups. Blood sample analysis remains the primary matrix, with distinctions between capillary and venous sampling influencing device design. Finally, both primary and tertiary healthcare centers are expanding their use of automated detection platforms, even as manual assays retain relevance in decentralized or resource-limited settings.

Key Regional Adoption and Infrastructure Insights

Regional dynamics reflect varied adoption trajectories and infrastructure maturity. In the Americas, leading diagnostic markets in North America are characterized by robust reimbursement frameworks and rapid uptake of molecular and sequencing technologies, whereas Latin America exhibits slower diffusion but growing interest in cost-effective immunoassays. Within Europe, Middle East & Africa, Western Europe demonstrates high penetration of advanced automated detection systems, the Middle East is investing heavily in laboratory modernization, and Africa continues to prioritize fundamental microbiology infrastructure. Meanwhile, Asia-Pacific is witnessing exponential growth, with nations like China, India, Japan, and Australia expanding their diagnostic capacities and local manufacturing ecosystems to meet surging demand for rapid bloodstream infection testing.

Key Company Strategies and Innovation Highlights

Leading companies are central to driving innovation, supply chain resilience, and global market reach. Abbott Laboratories remains at the forefront with a diversified molecular diagnostics portfolio, while Thermo Fisher Scientific Inc. leverages its broad instrumentation and reagent ecosystem to deliver end-to-end solutions. BioMérieux and Cepheid have carved niches in rapid pathogen identification platforms, whereas F. Hoffmann-La Roche Ltd continues to advance real-time PCR and next-generation sequencing offerings. Becton, Dickinson and Company and Bruker Corporation enhance laboratory efficiency through smart analytics tools and software integrations.

Diagnostic reagent specialists such as Diasorin S.p.A. and Pro-Lab Diagnostics focus on targeted immunoassays and culture media, while Cardinal Health and Fresenius Medical Care AG & Co. KGaA optimize distribution networks and service portfolios. Emergent innovators include Accelerate Diagnostics, Inc. with microarray research applications, Kurin Inc. and CorMedix Inc. pursuing novel antimicrobial detection chemistries, and Sepsis Alliance driving consensus guidelines. Pharma-based entrants like Merck & Co., Inc., Pfizer Inc., and Sanofi S.A. are expanding into diagnostics adjunct to therapeutic development. Academic collaborations with HiMedia Laboratories Pvt. Ltd. and ITL Health Group further strengthen regional manufacturing and validation capabilities, ensuring a dynamic competitive landscape.

Actionable Recommendations for Industry Leaders

To navigate this evolving environment, industry leaders should prioritize a multifaceted approach. First, investing in integrated platforms that combine rapid molecular assays with sequencing capabilities will address both acute diagnostic needs and epidemiological surveillance. Second, establishing strategic partnerships with contract manufacturers in tariff-advantaged regions will safeguard supply continuity and cost predictability. Third, adopting reagent rental or reagent-as-a-service models can transform capital constraints into flexible operational expenditure, enabling laboratories to scale testing in response to outbreak surges.

Fourth, tailoring solutions to regional infrastructure maturity-such as developing point-of-care immunoassays for emerging markets and high-throughput automated systems for mature labs-will maximize addressable market share. Fifth, forging collaborations with antibiotic stewardship programs and professional societies can elevate the clinical utility of new assays and accelerate guideline integration. Finally, leveraging real-world data analytics and artificial intelligence in software tools will unlock deeper insights into pathogen resistance patterns, guiding both diagnostic and therapeutic decision-making with increased precision.

Conclusion: Seizing the Future of Rapid, Resilient Diagnostics

Bloodstream infection diagnostics stands at a pivotal juncture where technological innovation, regulatory landscapes, and clinical imperatives converge. Stakeholders who embrace integrated testing strategies, resilient supply chains, and agile business models will lead the next wave of market growth. By aligning product development with diverse end-user needs-from emergency department point-of-care assays to centralized sequencing workflows-companies can deliver high-value solutions that improve patient outcomes and operational efficiency. Continuous collaboration across industry, healthcare institutions, and research consortia will further cement the role of advanced diagnostics in combating sepsis and antimicrobial resistance globally.

Market Segmentation & Coverage

This research report categorizes the Bloodstream Infection Testing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Chromatography Testing
  • Conventional Testing Methods
  • Molecular Testing
  • Immunoassays
  • Microarrays
  • Next-Generation Sequencing (NGS)
    • De Novo Sequencing
    • Sanger Sequencing
  • PCR (Polymerase Chain Reaction)
    • Multiplex PCR
    • Real-Time PCR
  • Bacterial Infections
    • Gram-Negative Bacteria
    • Gram-Positive Bacteria
  • Fungal Infections
  • Viral Infections
    • DNA Viruses
    • RNA Viruses
  • Clinical Applications
    • Inpatient Testing
  • Laboratory Testing
  • Academic and Research Institutes
  • Diagnostic Laboratories
  • Hospitals and Clinics
    • Emergency Departments
  • Instruments
  • Reagents and Kits
  • Software and Services
    • Analytics Tools
    • Data Management Software
  • Adults
  • Geriatrics
  • Neonates
  • Pediatrics
  • Blood Sample
    • Capillary Blood
    • Venous Blood
  • Automated Detection
  • Manual Detection
  • Primary Healthcare Centers
  • Tertiary Healthcare Centers

This research report categorizes the Bloodstream Infection Testing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bloodstream Infection Testing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Advacare Pharma
  • Bactiguard AB
  • Becton, Dickinson and Company
  • BioMérieux
  • Bruker Corporation
  • Cardinal Health
  • Cepheid
  • CorMedix Inc.
  • Diasorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Fresenius Medical Care AG & Co. KGaA
  • HiMedia Laboratories Pvt. Ltd
  • ITL Health Group
  • Johnson & Johnson Services, Inc
  • Kurin Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Pro-Lab Diagnostics
  • Sanofi S.A.
  • Sepsis Alliance
  • Thermo Fisher Scientific Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bloodstream Infection Testing Market, by Testing Type
8.1. Introduction
8.2. Chromatography Testing
8.3. Conventional Testing Methods
8.4. Molecular Testing
9. Bloodstream Infection Testing Market, by Technology Type
9.1. Introduction
9.2. Immunoassays
9.3. Microarrays
9.4. Next-Generation Sequencing (NGS)
9.4.1. De Novo Sequencing
9.4.2. Sanger Sequencing
9.5. PCR (Polymerase Chain Reaction)
9.5.1. Multiplex PCR
9.5.2. Real-Time PCR
10. Bloodstream Infection Testing Market, by Pathogen Type
10.1. Introduction
10.2. Bacterial Infections
10.2.1. Gram-Negative Bacteria
10.2.2. Gram-Positive Bacteria
10.3. Fungal Infections
10.4. Viral Infections
10.4.1. DNA Viruses
10.4.2. RNA Viruses
11. Bloodstream Infection Testing Market, by Application Area
11.1. Introduction
11.2. Clinical Applications
11.2.1. Inpatient Testing
11.3. Laboratory Testing
12. Bloodstream Infection Testing Market, by End User
12.1. Introduction
12.2. Academic and Research Institutes
12.3. Diagnostic Laboratories
12.4. Hospitals and Clinics
12.4.1. Emergency Departments
13. Bloodstream Infection Testing Market, by Product Type
13.1. Introduction
13.2. Instruments
13.3. Reagents and Kits
13.4. Software and Services
13.4.1. Analytics Tools
13.4.2. Data Management Software
14. Bloodstream Infection Testing Market, by Age Group of Patient
14.1. Introduction
14.2. Adults
14.3. Geriatrics
14.4. Neonates
14.5. Pediatrics
15. Bloodstream Infection Testing Market, by Sample Type
15.1. Introduction
15.2. Blood Sample
15.2.1. Capillary Blood
15.2.2. Venous Blood
16. Bloodstream Infection Testing Market, by Detection Mode
16.1. Introduction
16.2. Automated Detection
16.3. Manual Detection
17. Bloodstream Infection Testing Market, by Healthcare Setting
17.1. Introduction
17.2. Primary Healthcare Centers
17.3. Tertiary Healthcare Centers
18. Americas Bloodstream Infection Testing Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Bloodstream Infection Testing Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Bloodstream Infection Testing Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. Abbott Laboratories
21.3.2. Accelerate Diagnostics, Inc.
21.3.3. Advacare Pharma
21.3.4. Bactiguard AB
21.3.5. Becton, Dickinson and Company
21.3.6. BioMérieux
21.3.7. Bruker Corporation
21.3.8. Cardinal Health
21.3.9. Cepheid
21.3.10. CorMedix Inc.
21.3.11. Diasorin S.p.A.
21.3.12. F. Hoffmann-La Roche Ltd
21.3.13. Fresenius Medical Care AG & Co. KGaA
21.3.14. HiMedia Laboratories Pvt. Ltd
21.3.15. ITL Health Group
21.3.16. Johnson & Johnson Services, Inc
21.3.17. Kurin Inc.
21.3.18. Merck & Co., Inc.
21.3.19. Novartis AG
21.3.20. Novo Holdings A/S
21.3.21. Pfizer Inc.
21.3.22. Pro-Lab Diagnostics
21.3.23. Sanofi S.A.
21.3.24. Sepsis Alliance
21.3.25. Thermo Fisher Scientific Inc.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. BLOODSTREAM INFECTION TESTING MARKET MULTI-CURRENCY
FIGURE 2. BLOODSTREAM INFECTION TESTING MARKET MULTI-LANGUAGE
FIGURE 3. BLOODSTREAM INFECTION TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2030 (%)
FIGURE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOODSTREAM INFECTION TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CHROMATOGRAPHY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CONVENTIONAL TESTING METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DE NOVO SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DNA VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RNA VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INPATIENT TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ANALYTICS TOOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRIMARY HEALTHCARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TERTIARY HEALTHCARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 120. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 121. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 122. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 123. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 124. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 125. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 126. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 127. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 128. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 131. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 133. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 134. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 135. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 136. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 137. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 141. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 142. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 212. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 213. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 214. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 215. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 216. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 217. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 218. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 219. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 220. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 221. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 223. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 225. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 226. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 227. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 228. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 229. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 230. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 231. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 232. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 233. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 234. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 235. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 236. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 237. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 238. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 239. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 241. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 243. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 244. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 245. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 246. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 247. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 252. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 269. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 270. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 271. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 277. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 279. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 280. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 282. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY DETECTION MODE, 2018-2030 (USD MILLION)
TABLE 283. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AGE GROUP OF PATIENT, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BLOODS

Companies Mentioned

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Advacare Pharma
  • Bactiguard AB
  • Becton, Dickinson and Company
  • BioMérieux
  • Bruker Corporation
  • Cardinal Health
  • Cepheid
  • CorMedix Inc.
  • Diasorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Fresenius Medical Care AG & Co. KGaA
  • HiMedia Laboratories Pvt. Ltd
  • ITL Health Group
  • Johnson & Johnson Services, Inc
  • Kurin Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Pro-Lab Diagnostics
  • Sanofi S.A.
  • Sepsis Alliance
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bloodstream Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Bloodstream Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Bloodstream Infection Testing - Global Strategic Business Report - Product Image

Bloodstream Infection Testing - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
North America Bloodstream Infection Testing Market, By Country, Competition, Forecast & Opportunities, 2019-2029F - Product Image

North America Bloodstream Infection Testing Market, By Country, Competition, Forecast & Opportunities, 2019-2029F

  • Report
  • 132 Pages
  • North America
From
Blood Culture Test Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Technology; Application; and End-User - Product Image

Blood Culture Test Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Technology; Application; and End-User

  • Report
  • 142 Pages
  • Global
From
Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033 - Product Image

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From

About the Bloodstream Infection Test Market

The Bloodstream Infection Test market is a subset of the larger Infectious Disease Testing market. It is used to detect the presence of bacteria, fungi, and viruses in the bloodstream. The test is typically performed on a sample of blood taken from a patient, and the results are used to diagnose and treat infections. The test can also be used to monitor the effectiveness of treatments. The Bloodstream Infection Test market is highly competitive, with a range of products available from different manufacturers. These products vary in terms of accuracy, cost, and turnaround time. The market is also subject to regulatory requirements, which can affect the availability of certain products. Some companies in the Bloodstream Infection Test market include Abbott, Becton Dickinson, Cepheid, DiaSorin, Hologic, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.